An Open Label, Phase I/IIa, Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Intravenous Volasertib (BI 6727) in Combination with Decitabine in Patients with Acute Myeloid Leukemia

Diseases and Conditions Researched

Leukemia, not otherwise specified; Myeloid and Monocytic Leukemia

What is the purpose of this trial?

The primary objective is to investigate the maximum tolerated dose (MTD), safety and efficacy of volasertib in combination with decitabine in patients with acute myeloid leukaemia (AML).


Participation Guidelines

Age: Any

Click here for detailed participation information for this trial.

Sponsor: Boehringer Ingelheim Pharmaceuticals, Inc.
Dates:
Last Updated:
Study HIC#: 1311013040